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Background: MitoQ is a mitochondria-targeted derivative of the antioxidant ubiquinone, with antioxidant and
anti-apoptotic functions. Reactive oxygen species are involved in many inflammatory diseases including
inflammatory bowel disease. In this study, we assessed the therapeutic effects of MitoQ in a mouse model of
experimental colitis and investigated the possible mechanisms underlying its effects on intestinal inflammation.
Methods: Reactive oxygen species levels and mitochondrial function were measured in blood mononuclear cells of
patients with inflammatory bowel disease. The effects of MitoQ were evaluated in a dextran sulfate sodium-induced
colitis mouse model. Clinical and pathological markers of disease severity and oxidative injury, and levels of
inflammatory cytokines in mouse colonic tissue were measured. The effect of MitoQ on inflammatory cytokines
released in the human macrophage-like cell line THP-1 was also analyzed.
Results: Cellular and mitochondrial reactive oxygen species levels in mononuclear cells were significantly higher in
patients with inflammatory bowel disease (P <0.003, cellular reactive oxygen species; P <0.001, mitochondrial
reactive oxygen species). MitoQ significantly ameliorated colitis in the dextran sulfate sodium-induced mouse
model in vivo, reduced the increased oxidative stress response (malondialdehyde and 3-nitrotyrosine formation),
and suppressed mitochondrial and histopathological injury by decreasing levels of inflammatory cytokines IL-1 beta
and IL-18 (P <0.001 and P <0.01 respectively). By decreasing mitochondrial reactive oxygen species, MitoQ also
suppressed activation of the NLRP3 inflammasome that was responsible for maturation of IL-1 beta and IL-18.
In vitro studies demonstrated that MitoQ decreases IL-1 beta and IL-18 production in human THP-1 cells.
Conclusion: Taken together, our results suggest that MitoQ may have potential as a novel therapeutic agent for
the treatment of acute phases of inflammatory bowel disease.
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Inflammatory bowel disease (IBD) is a chronic relapsing
inflammatory disorder of the intestine that comprises
two major clinical forms, namely, ulcerative colitis (UC)
and Crohn’s disease (CD). Clinical features consist of
diarrhea, abdominal pain, rectal bleeding and weight loss.
The complications observed in colonic manifestations are
bowel strictures, obstruction, abscess formation and perfor-
ation. In addition, IBD leads to extra-colonic inflammatory
manifestations in many organs including the joints, eyes,
skin and liver [1]. Conventional medications such as corti-
costeroids and immune-modulators are the first line of
therapy for IBD. However, remission from corticosteroids is
only maintained for a short period, and treatment impairs
general immunity. A recently developed monoclonal
antibody targeting TNF-α shows efficacy in inducing
and maintaining remission, but has serious side effects,
including an increased risk of infection. Moreover,
some patients do not show adequate responses [2,3].
Systematic review of population-based studies between
1950 and 2010 shows that prevalence and incidence of
IBD are dramatically increasing throughout the world
[4]. Therefore, there is a need to develop safer and
more effective therapies for IBD.
The exact etiology of IBD is still not fully understood,
but dysfunctional immunoregulation of the gut plays a
crucial role in the pathogenesis of IBD [5]. IL-1 beta
and IL-18 are the major pro-inflammatory cytokines
that promote activation of both the innate and adaptive im-
mune responses [6,7]. Hypoxia-induced transcription factor
forkhead box p3 (Foxp3) enhances regulatory T cells, which
are essential for immune tolerance and play a crucial role
in the limitation of excessive helper T cells induction and
inflammatory response [8]. But, inflammatory cytokines
including IL-1 beta inhibit Foxp3 function, induce dif-
ferentiation of helper T cells, and can cause T cell-
mediated inflammation [9,10]. High levels of IL-1 beta
and IL-18 expression in patients with IBD [11,12] and
their correlation with disease activity [13] have been
well described, and indicate that these cytokines play an
important role in promoting localized inflammation in
IBD. IL-1 beta and IL-18 are expressed as inactive precur-
sors and activated after cleavage by the NACHT, LRR and
PYD domains-containing protein 3 (NLRP3) inflammasome,
whose mutations have been associated with CD [14]. The
NLRP3 inflammasome is a multi-protein, caspase-1 activat-
ing complex, and its dysregulation is strongly associated
with many inflammatory diseases [15]. Several reports have
shown that the NLRP3 inflammasome plays a pathological
role in experimental colitis [16,17], and that activation of the
NLRP3 inflammasome is mediated by mitochondrial react-
ive oxygen species (mtROS) [18-20]. Moreover, many stud-
ies have shown that ROS mediate intestinal tissue injury,
and that administration of antioxidants or overexpressionof antioxidant enzymes leads to amelioration of experimen-
tal colitis. Furthermore, a strong association between oxida-
tive stress and IBD has been observed in many human
studies [21]. A possible role of mitochondrial dysfunction
in the pathogenesis of IBD was reported in clinical cases
[22,23], and these data also suggested that mtROS play a
role in the pathogenesis of IBD.
MitoQ is an orally available mitochondria-targeted de-
rivative of the antioxidant ubiquinone. MitoQ comprises
a lipophilic triphenylphosphonium (TPP) cation that drives
rapid permeation of phospholipid bilayers and leads to an
accumulation within mitochondria. In the mitochondrial
matrix, MitoQ is continually reduced by the respiratory
chain to its active form and protects mitochondria from
oxidative damage. Due to the characteristic of selective
accumulation and continual recycling within mitochondria,
MitoQ has been demonstrated in vitro and in vivo to be
protective against many oxidative damage-related patholo-
gies, including ischemia-reperfusion injury [24], cardiovas-
cular diseases [25,26], ethanol-dependent hepatosteatosis
[27] and sepsis [28]. MitoQ has successfully been tested in
phase I and phase II clinical trials and shown to be effective
against liver damage in patients with hepatitis C infection
[29]. Importantly, these clinical trials showed that MitoQ
has no severe adverse effects.
In this study, we hypothesized that MitoQ might decrease
the excessive activation of the NLRP3 inflammasome, and
thus attenuate acute phases of IBD. Therefore, we tested if
MitoQ can function as a therapeutic agent to treat acute
colonic injury in a mouse model of dextran sulfate sodium
(DSS)-induced colitis.
Methods
Peripheral blood mononuclear cells
Blood samples were obtained from seven patients with ac-
tive CD (four men, three women), seven with active UC (five
men, two women) and 14 healthy volunteers (five women,
nine men) as normal controls. Blood samples were carefully
layered over 3 to 5 ml of polymorphonuclear leukocyte
isolation medium (Cedarlane Laboratories, Hornby, ON,
Canada). Samples were centrifuged at 450 g for 30 minutes
at 18°C. At the end of centrifugation, the top band that
consisted of mononuclear cells (MNC) was harvested with
a Pasteur pipette, repeatedly washed with Hank’s balanced
salt solution and then subjected to ROS levels measure-
ment and preparation of mitochondrial proteins. This
study was approved by the Institutional Review Board of
the Kyung Hee University of Korea, College of Medicine.
All participants signed a written informed consent form
before any protocol-specific procedure was carried out.
Reactive oxygen species analysis
ROS levels were measured with the fluorescent probes 2ʹ,
7ʹ–dichlorofluoresceindiacetate (DCF-DA) and MitoSOX.
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at 37°C for 30 minutes and washed with 1 ml PBS.
Fluorescence was determined with excitation at 488 nm
and emission at 525 nm by flow cytometer (FACSCalibur;
Becton-Dickinson, Franklin Lakes, NJ, USA).
Preparation of mitochondrial fraction and
mitochondrial proteins
Preparation of mitochondrial fraction and proteins were
performed as previously described [30]. The isolated
mitochondria were subjected to mitochondrial electron
transport chain complex expression measurements as
previously described [31].
Animals
Female Balb/c (wild type; WT) mice (6 to 7 weeks of
age; weighing 18 to 20 g) were purchased from Central
Lab. Animal, Inc. (Seoul, Korea). Four to five animals
were housed per cage and fed standard mice chow pellets,
had access to tap water supplied in bottles, and were
acclimatized 7 days before they went into experiments. The
experimental protocol was approved by the Institutional
Animal Care and Use Committee of Kyung Hee University
(Seoul, Korea).
Induction of colitis and treatment
DSS(molecular weight, 36,000-50,000) was purchased from
MP Biomedicals (Illkirch, France). Mice were divided into
four groups: control group (WT), DSS-induced colitis
group (WT+DSS), DSS with decyltriphenylphosphonium
bromide (dTPP)-treated group (DSS+dTPP), and DSS with
MitoQ-treated (DSS+MitoQ) group. Considering the fast
recovery of DSS-induced colitis in mice after DSS with-
drawal [32], we gave 4% DSS in their drinking water from
day 0 to day 7, followed by 1% DSS for maintaining path-
ology as described previously [33]. None of the mice in this
study died before termination of the experiment at day 21.
Control mice were given tap water. MitoQ and dTPP were
administered orally at a final concentration of 500 μM from
day 7 for 14 days until the end of experiments [34]. All
compounds were dissolved in water and given fresh every
third day. Clinical scores of colitis, such as weight change
and colorectal bleeding, were observed. Mice were then
sacrificed and the colons were removed, cleaned, and length
was measured.
Isolation of peritoneal macrophages
Mice were anesthetized with isoflurane, sacrificed by
cervical dislocation, and injected with 10 ml of PBS.
After 30 seconds of abdominal massaging, peritoneal
lavage was performed. Collected peritoneal lavage was
centrifuged and plated in 60 well plates and incubated
for 2 hours. Adherent cells were analyzed in subse-
quent experiments.Histological analysis
Distal colonic sections of 1.5 cm were fixed in 10% neutral-
buffered formalin, processed for paraffin embedding, sec-
tioned at 5 μm and stained with hematoxylin and eosin
according to standard protocols. Histological scoring was
performed in a blinded fashion by a pathologist using a com-
bined score of inflammatory cell infiltration (score 0 to 3)
and tissue damage (score 0 to 3). Focally increased numbers
of inflammatory cells in the lamina propria were scored as 1,
confluence of inflammatory cells extending into the sub-
mucosa as 2, and transmural extension of the infiltrate as 3.
For tissue damage, discrete lymphoepithelial lesions were
scored as 1, mucosal erosions as 2, and extensive mucosal
damage or extension through deeper structures of the bowel
as 3. The two equally measured sub-scores were added and
the combined histological colitis severity ranged from 0 to 6.
Transmission electron microscopy
Colon tissues were fixed in fixative solution (2% glutaral-
dehyde and 1% formaldehyde in 0.1 M sodium cacodylate
buffer, pH 7.4) for 2 hours and washed with sodium
cacodylate buffer. After fixing with 1% osmium tetraoxide,
tissues were washed and dehydrated by replacement of
ascending series of alcohol. Tissues were embedded in
epon and propylene oxide (1:1) and sectioned using an
ultramicrotome (Reichert Ultracut S, Leica Microsystems,
Wetzlar, Germany). Ultrastructural changes were observed
using a transmission electron microscope (Zeiss EM 902A,
Oberkohen, Germany) under 80 kV.
Immunohistochemical analysis
Colons were fixed in 10% buffered formalin, dehydrated,
embedded in paraffin and sectioned at 5 μm slices. Sections
were stained with anti-malondialdehyde antibody (Genox
Corp., Baltimore, MD, USA) or anti-nitrotyrosine antibody
(Cayman Chemical, Ann Arbor, MI, USA) overnight,
followed by incubation with biotin-labeled anti-rabbit anti-
body. Both sections were counterstained by hematoxylin
(Gene Tex, Irvine, California, USA) and mounted with
(Vector laboratories, Burlingame, CA, USA). The im-
munostained sections were visualized with an EnVision
Detection Kit (Dako, CA, USA).
Cytokine measurement
Colon homogenates were centrifuged at 15,000 rpm for
15 minutes. The amounts of IL-1 beta and IL-18 were
quantified by ELISA (MBL and R&D Systems, Minneapolis,
MN, USA) according to the manufacturer’s protocol.
Reverse transcription-PCR
For the analysis of IL-1 beta and IL-18 mRNA, total RNA
was extracted from colon tissue using Trizol reagent
(Invitrogen, Carlsbad, CA, USA) and 1 μg was amplified
using the following specific primers: IL-1 beta forward,
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The amplified products were visualized on a 1% agarose
gel, and the amplified GAPDH fragment was used as an
internal control for RT-PCR.
Cell culture
Human THP-1 cells were grown in Roswell Park Memorial
Institute medium, supplemented with 10% fetal bovine
serum, 100 units/ml of penicillin and 100 μg/ml of strepto-
mycin. Cells were differentiated with 100 nM phorbol
12-myristate 13-acetate (Sigma Chemical Co, St Louis,
MO, USA) for 24 hours. Cells were then treated with H2O2
(5 mM) for 6 hours with or without MitoQ (50 to 150 nM).
Before collecting supernatants, cells were subsequently
stimulated by ATP for 30 minutes. Supernatants and cell
lysates were analyzed in subsequent experiments.
Immunoprecipitation and western blotting analysis
Immunoprecipitation (IP) was performed as described
previously [35]. The IP samples and colon homogenates
were separated using 8% to 13.5% SDS-polyacrylamide gels.
The following primary antibodies were used: each subunit
of mitochondrial complexes (MitoScience, Eugene, OR,
USA), NLRP3 (mouse monoclonal; Adipogen, Inc., Incheon,
Korea), apoptosis-associated speck-like protein containing a
CARD (ASC; rabbit monoclonal, Adipogen, Inc.), caspase-1
(rabbit polyclonal; Santa Cruz Biotechnology, Santa Cruz,
CA, USA), IL-18 (mouse monoclonal; R&D Systems), IL-1
beta (rabbit polyclonal; BioVision, Inc., Milpitas, CA, USA),
thioredoxin (TRX;rabbit monoclonal; AbFrontier, Seoul,
Korea), TRX interacting protein (TXNIP; goat monoclonal;
MBL International, Woburn, MA, USA) and actin (goat
polyclonal; Abcam, Cambridge, MA, USA). Blots were
washed with Tris-buffered saline with Polyethylene glycol
sorbitan monolaurate 20 and developed with enhanced
chemiluminescence reagents (Santa Cruz Biotechnology).
Statistical analysis
Results were expressed as mean ± standard error (SE).
Error bars represent the mean ±SE of at least three inde-
pendent experiments. The difference between two mean
values was analyzed using a Student’s t-test. The difference
was considered statistically significant when P <0.05.
Results
Reactive oxygen species levels increase in the mononuclear
cells of patients with inflammatory bowel disease
To determine whether there was an increase in ROS
during IBD, we measured ROS levels via flow cytometryusing the ROS probes DCF-DA and MitoSOX in the
MNC of patients with IBD. Blood samples were obtained
from patients before and after treatment. Patients received
standard drugs in combination, as illustrated in Additional
file 1: Table S1. Interestingly, ROS levels, as measured by
both probes, were increased in the MNC of patients
with active IBD. However, ROS levels were significantly
decreased in patients in clinical remission (Figure 1A).
To assess whether the changes in ROS levels were associ-
ated with changes in mitochondrial function, we checked
the expression levels of mitochondrial electron transport
chain (mtETC) complex subunits. As shown in Figure 1B,
expression levels of mtETC complexes were increased
during IBD, but decreased after treatment and clinical
remission was achieved. We also checked induction of
manganese superoxide dismutase, which responds to
elevated oxidative stress in mitochondria. The expression
level of MnSOD was increased during IBD and decreased
after treatment. Voltage dependent anion channel was used
to verify that mitochondrial proteins were equally loaded
for western blotting analysis. From these results, we con-
cluded that changes in mitochondrial function and mtROS
levels correlate with IBD.
MitoQ attenuates dextran sulfate sodium-induced colitis
Since elevated ROS levels and changes in mitochondrial
function seemed to correlate with the pathogenesis of
IBD, we investigated the therapeutic effect of MitoQ on
DSS-induced mouse colitis. To induce severe colitis, we
treated mice with 4% DSS for 7 days and then 1% DSS
for another 14 days in their drinking water. MitoQ or
dTPP was administered from day 7 until the end of the
experiment (Figure 2A). dTPP, which contains the same
lipophilic cation as MitoQ but lacks antioxidant activity,
was used as a negative control. Body weight loss was
significantly increased in mice with DSS-induced colitis,
and treatment with dTPP did not reverse this weight
loss. However, mice with DSS-induced colitis treated with
MitoQ gained weight similar to control mice (Figure 2B).
The colon length shortening and bloody stool score
were also significantly increased in mice treated with
DSS or DSS+dTPP. Once again, MitoQ administration
inhibited the DSS-induced bloody stool and decreased
the colon length shortening (Figure 2C,D). Distal colonic
sections from DSS and DSS+dTPP-treated mice revealed
multifocal inflammatory cell infiltration and edema with
crypt and epithelial cell destruction and ulceration. By
contrast, no mucosal inflammation was observed in colonic
sections of DSS+MitoQ-treated mice (Figure 2E,F). Colitis
score was also significantly lower in MitoQ-treated
colitis mice than in the DSS and DSS+dTPP-treated
mice (Figure 2G). These data reveal that MitoQ inhibits
clinical and histological changes in the colon associated
with DSS-induced colitis.
Figure 1 Mitochondrial reactive oxygen species generation in patients with inflammatory bowel disease. (A) Intracellular H2O2 and
mitochondrial peroxynitrate levels in mononuclear cells of patients with IBD before (IBD untr) and after treatment (IBD treat), compared with
healthy volunteers (cont). Results are expressed as means ±SE. *P <0.003, **P <0.001. (B) Western blotting analysis of the expression patterns of
various mtETC complex subunits from mitochondria isolated from peripheral blood MNC of patients. pat – patient. IBD, inflammatory bowel
disease; mtETC, mitochondrial electron transport chain; MNC, mononuclear cells.
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To demonstrate the effect of MitoQ on mitochondria
during colitis, we first studied mitochondrial structural
changes. Electron microscopy of the colon of control
mice revealed good preservation of normal mitochondrial
structure (Figure 3A, left). In colon tissue in DSS and
DSS+dTPP-treated mice,the majority of mitochondria had
alterations in size and matrix. In some mitochondria, the
matrix totally disappeared and only the outer membrane
remained. In others, the cristae were disorganized because
of edema in the matrix (Figure 3A, middle). MitoQ treat-
ment reduced the morphological and mitochondrial injury
during colitis (Figure 3A, right). There was a significant
increase of malondialdehyde formation (a marker of lipid
peroxidation, brown staining) in the colon during colitis
(Figure 3B, middle) and MitoQ dramatically reduced the
malondialdehyde formation (Figure 3B, right). Colitis was
also associated with increased mitochondrial nitrotyrosine
formation in the colon, an index of peroxynitrate-mediated
protein nitration (Figure 3C, middle). However, MitoQ
was protective against nitrate damage of the colon during
colitis, as shown in Figure 3C (right). These data reveal thatMitoQ protects mitochondria and reduces oxidative
damage in the colon of mice with DSS-induced colitis.
MitoQ inhibits caspase-1 activation through suppression
of TXNIP binding to NLRP3 during colitis
To clarify the mechanism of MitoQ in attenuation of
colitis, we investigated the function of the NLRP3
inflammasome. The NLRP3 inflammasome comprises
adaptor proteins ACS and caspase-1. It isknown that
TXNIP binds to the leucine-rich repeat domain of
NLRP3 and activates the inflammasome during oxidative
stress [20]. TXNIP binds to TRX and negatively regulates
its redox function in resting cells [36]. Oxidized TRX
during oxidative stress is dissociated from the TXNIP-
TRX complex, and leads to the interaction of TXNIP
with NLRP3. Therefore, we hypothesized that binding
of TXNIP to NLRP3 activates the inflammasome, which
causes autocleavage of caspase-1 and the release of mature
cytokines IL-1 beta and IL-18 during colitis. Western blot-
ting analysis revealed that expression of the inflammasome
complex proteins such as NLRP3 and ASC are not
changed during colitis, but procaspase-1 is increased in
Figure 2 Therapeutic potential of MitoQ for dextran sulfate sodium-induced colitis. (A) Experimental design for DSS-induced colitis in
mice. 4% DSS was administered to WT mice from day 0 to day 7 followed by 1% of DSS for the duration of the experiment. Two groups of mice
additionally received dTPP and MitoQ from day 7. (B) Body weight of mice was measured every 3 days and presented as a percentage of their
initial weight, n = 5 mice per group. (C) Bloody stool score on the 10th day. (D) Lengths of the freshly removed colons were measured from
rectum to ileocecal junction. (E) Representative distal colon sections stained with hematoxylin and eosin. The magnification is indicated. (F) Crypt
damage. (G) Colitis score. For all samples, results are expressed as mean ±SE. n = 3, *P <0.001. DSS+dTPP, DSS with dTPP-treated mice;
DSS+MitoQ, DSS with MitoQ-treated mice; NS, not significant; WT, control mice; WT+DSS, DSS-treated mice.
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DSS+dTPP-treated mice. However, procaspase-1 was not
cleaved in control and MitoQ-treated mice (Figure 4A).
Next, we performed co-IP to check the interaction
between TXNIP and NLRP3, and revealed that TXNIP
is dissociated from TRX in DSS- and DSS+dTPP-
treated mice (Figure 4B). During colitis, the dissociated
TXNIP was bound to NLRP3, and this interaction was
blocked by MitoQ treatment (Figure 4C). To gain moreinsight into the mechanism of oxidative stress-induced
colitis, we isolated mouse peritoneal macrophages and
measured mitochondrial ROS levels. Macrophages of
DSS+MitoQ-treated mice released lower levels of ROS
compared with macrophages of DSS- and DSS+dTPP-
treated mice (Figure 4D). Therefore, we concluded that
activation of NLRP3 inflammasome during colitis is
dependent on the interaction of TXNIP and NLRP3,
and that this activation is mediated by mtROS.
Figure 3 MitoQ attenuates mitochondrial alteration and oxidative damage during DSS-induced colitis. (A) Representative transmission
electron micrographs of colon. The magnification is indicated. Similar histological profiles were seen in three separate colons per group.
(B) Sections of colonic tissues were subjected to immunohistochemical analysis with an antibody against malondialdehyde. The magnification is
indicated. (C) Sections of colonic tissues were subjected to immunohistochemical analysis with an antibody against 3-nitrotyrosine staining. The
magnification is indicated.
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cytokines IL-1 beta and IL-18 during colitis
We next asked whether an activated inflammasome
leads to enhanced release of IL-1 beta and IL-18 during
colitis. Release of the active inflammatory cytokines IL-1
beta and IL-18 is mediated by a two-step process: first,
recognition of pro-inflammatory signals by pattern recog-
nition receptors on host cells and activation of pro-IL-1
beta and pro-IL-18 promoters; second, activation of the
inflammasome by danger signals, resulting in activation of
caspase-1 and cleavage of pro-IL-1 beta and pro-IL-18
[37]. Therefore, we evaluated how MitoQ affects the
release of these cytokines in colon homogenates. Levels of
IL-1 beta and IL-18 were significantly higher in DSS- and
DSS+dTPP-treated mice than in control and DSS+MitoQ-
treated mice, suggesting that MitoQ suppresses the release
of these cytokines (Figure 5A,B). Furthermore, the mRNA
levels of IL-1 beta and IL-18 were higher in DSS- and
DSS+dTPP-treated mice, but suppressed with MitoQ
treatment (Figure 5C). Lastly, western blotting analysisdemonstrated the increased level of cleaved forms of
caspase-1, IL-1 beta and IL-18 in the colon of DSS- and
DSS+dTPP-treated mice, but the decreased cleavage in
control and DSS+MitoQ-treated mice (Figure 5D). These
data clearly demonstrate that MitoQ not only suppresses
release of the active forms of IL-1 beta and IL-18, but also
their transcriptional up-regulation.
MitoQ decreases the levels of IL-1 beta and IL-18 in a human
macrophage cell line
Finally, we investigated the in vitro effect of MitoQ on
IL-1 beta and IL-18 production in a human macrophage-
like cell line, THP-1. ELISA analysis revealed that MitoQ
dose-dependently reduces the release of these cytokines
whereas it is induced by H2O2 and ATP (Figure 6A,B).
Furthermore, co-IP studies revealed that TXNIP is disso-
ciated from TRX and binds to NLRP3, and this interaction
is blocked by MitoQ treatment (Figure 6C). Lastly, MitoQ
also suppressed mtROS generation in a dose-dependent
manner (Figure 6D). These results further confirmed the
Figure 5 MitoQ suppresses caspase-1-mediated IL-1 beta and IL-18 release during colitis. ELISA assay for (A) IL-1 beta or (B) IL-18 were performed
in colon homogenates. Results are expressed as mean ±SE. n=5. *P <0.001,**P<0.01. (C) mRNA expression levels of IL-1 beta and IL-18 in colon tissue were
examined by RT-PCR. (D) Cleavages of caspase-1, IL-1 beta and IL-18 were analyzed by western blotting analysis in colon homogenates.
Figure 4 MitoQ inhibits caspase-1 activation through suppression of TXNIP binding to NLRP3 during colitis. (A) Western blotting analysis
reveals expression of the NLRP3 inflammasome components in mouse colon homogenates. (B) Dissociation of the TXNIP-TRX complex upon
MitoQ treatment, as revealed by co-immunoprecipitation. (C) Co-immunoprecipitation and western blotting analysis identify the interaction of
TXNIP with NLRP3. IP, immunoprecipitation; input of cell extract without immunoprecipitation ensures equal loading. (D) Effect of MitoQ on
mtROS production in peritoneal macrophages. Results are expressed as mean ±SE. n= 5. *P <0.01.
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Figure 6 Effect of MitoQ on human THP-1 cells. (A) IL-1 beta and (B) IL-18 release in response to H2O2 or ATP were analyzed by ELISA. Results
are expressed as mean ±SE. n=5,*P<0.001. (C) The interaction between TXNIP and NLRP3 was examined by co-IP and western blotting analysis.
(D) mtROS production in THP-1 cells. Cells were differentiated for 24 hours with 100 nM phorbol 12-myristate 13-acetate. Results are expressed as
mean ±SE. *P<0.001.
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by reducing oxidative stress and inflammatory cytokines.
Discussion
Here, we for the first time show that administration of
MitoQ decreases the severity of DSS-induced colitis in
mice. In addition, scavenging mtROS by MitoQ resulted
in a significant decrease of IL-1 beta and IL-18 in DSS-
induced colitis. Consequently, our results provide insights
into the role of mtROS in the pathogenesis of IBD, and
suggest that MitoQ may have therapeutic potential as a
new treatment for human IBD.
Oxidative injury induced by increased ROS levels has
been demonstrated in patients with IBD and in experi-
mental animals [21]. Also, a randomized controlled trial
reported that supplementation of antioxidants resulted
in significant clinical improvement of patients with UC
[38], indicating that ROS may have a causative role in
IBD. By contrast, other randomized controlled trials
showed that antioxidant supplementation has no effect on
activity of the disease. The reasons for this discrepancy in
patients with IBD remain unknown. Since the treatmentoutcomes of antioxidants are affected by several factors
including dosage, duration, phase of the disease, and
antioxidant potency [39,40], it may not be easy to clarify
reasons for the contrasting results in clinical trials. A num-
ber of different cellular sources of ROS such as NADPH
oxidase, inducible nitric oxide synthase, myeloperoxidase
and xanthine oxidase have already been reported [41,42].
Here, we propose that mitochondria are the major source
of ROS generation in IBD, and thus targeting mtROS may
be important for understanding the therapeutic efficacy
of antioxidants in patients with IBD. The reasons are as
follows: first, we revealed that mtROS generation are
significantly increased and expression levels of mtETC
components are altered in the MNC of patients with
IBD, all of which can be normalized after treatment with
standard medications (Figure 1); second, we revealed
that ROS levels and oxidative injury are increased in
DSS-induced mouse colitis, but suppressed by treatment
with MitoQ (Figures 3B,C and 4D); finally, other reports
also suggested that mitochondrial alterations are import-
ant for IBD and CD, including the morphological changes
of mitochondria in enterocytes of patients with IBD [43],
Figure 7 Schematic representation of the mechanism of action
of MitoQ during colitis. Increased generation of mtROS in the
damaged epithelium and activated macrophages leads to dissociation
of TXNIP from the TXNIP-TRX complex. Dissociated TXNIP binds to
NLRP3 protein and activates the NLRP3 inflammasome complex, which
is responsible for cleavage of pro-inflammatory cytokines pro-IL-1 beta
and pro-IL-18 into their active forms, thereby increasing intestinal
permeability and tissue injury. Moreover, the NLRP3 inflammasome
complex activates the adaptive immune system and exacerbates
inflammation. Suppressing mtROS with MitoQ can suppress this
pathway and inhibit cytokines release, thereby ameliorating
inflammation during colitis.
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immune peripheral cells of patients with CD, and the
functional defects at complex III and IV in isolated muscle
mitochondria [23]. In addition, there are many evidences
for a role of mtROS in hypoxia during inflammation [44].
Mucosal inflammation including vasculitis, vasoconstric-
tion, thrombosis and edema contributes to inflammatory
hypoxia in the intestine. Adaptation to hypoxia relies on
the hypoxia-inducible factor, which in turn contributes to
the induction of mucosal barrier genes [45,46]. But hypoxia
also leads to increased expression of pro-inflammatory
mediators [47,48] and increased generation of mtROS
[49], and could promote tumor growth [50,51]. Although
physiological level of ROS is important for hypoxia-
inducible factor stabilization and phagocytosis, ROS
are also considered to be second messengers for muco-
sal injury during IBD. In addition, inhibition of mtROS
resulted in restoration of regulatory T cells induction
[52]. These findings suggest that prolonged hypoxia
can drive a robust inflammatory response that contributes
to hypoxia-induced inflammation. Therefore, suppress-
ing overgenerated mtROS might help to attenuate intes-
tinal inflammation by reducing hypoxia and controlling
T cell activation.
MitoQ is a well-established mitochondria-targeted anti-
oxidant, and consists of a lipophilic TPP cation covalently
linked to ubiquinone, which is the active antioxidant moiety
of coenzyme Q. The adsorbed MitoQ in the mitochondrial
inner membrane acts as an antioxidant and ubiquinone is
rapidly reduced to its active ubiquinol form by complex II.
MitoQ shows good pharmacokinetic behavior and was
safely administered as a daily oral tablet to patients for
a year in phase 2 trials [53]. Furthermore, it has been
shown to have good antioxidative, anti-inflammatory and
anti-apoptotic effects in many in vivo and in vitro studies
[24-29]. In this study, we showed that MitoQ significantly
improves clinical and histological changes in the DSS-
induced mouse model of colitis (Figure 2A-G) by reducing
oxidative stress and restoring mitochondrial alterations
(Figure 3). These results suggest that mtROS may play
an important role in IBD and indicate that MitoQ is a
promising candidate for treatment of human IBD.
IL-1 beta and IL-18 are members of the IL-1 family of
cytokines, which play major roles in the pathogenesis of
IBD. Inflammatory cytokine IL-18 induces IL-1 beta,
TNF-α and IFN-γ, and thus leads to severe gut inflam-
mation [54]. IL-1 beta increases intestinal permeability
[55] and promotes Th17 responses in the gut [10]. Such
roles for IL-1 beta and IL-18 in IBD are supported by
several studies. For example, it was reported that
blockage of IL-1 beta [56,57] or neutralization of IL-18
[58,59] reduces intestinal inflammation. Additionally,
homozygous knock-out of NLRP3 and caspase-1 genes, or
inhibition of caspase-1 by a specific inhibitor, protectsmice from DSS-induced colitis [16,17,60,61]. The precur-
sors of IL-1 beta and IL-18 are cleaved and activated by
the cytosolic caspase-1 activating NLRP3 inflammasome,
whose physiological activation may be critical in the main-
tenance of intestinal homeostasis. However, excessive acti-
vation of NLRP3 inflammasome leads to severe pathology.
NLRP3 inflammasome activation is mediated by ROS via
the ROS-sensitive ligand, TXNIP [20]. ROS induce the dis-
sociation of TXNIP from TRX and allow TXNIP to bind
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of ROS responsible for NLRP3 inflammasome activation,
our results suggest that mtROS are responsible for its
activation. Consistent with this, recent studies revealed
that inflammasome activation was observed in mice
lacking NADPH oxidase subunits, and in patients with
chronic granulomatous disease characterized by defects
in NADH-oxidase subunits [62]. In the present study,
we showed that MitoQ suppresses ROS-promoted dis-
sociation of TXNIP from TRX, inhibits the interaction
between TXNIP and NLRP3 (Figure 4), and significantly
decreases levels of IL-1 beta and IL-18 in the colons of
mice with DSS-induced colitis (Figure 5A,B). Furthermore,
in vitro studies demonstrated that MitoQ also suppresses
the release of IL-1 beta and IL-18 from human THP-1 cells
(Figure 6A,B).
Finally, we conclude that overgeneration of mtROS dur-
ing IBD leads to increase of inflammatory cytokines IL-1
beta and IL-18 via activation of the NLRP3 inflammasome.
Active inflammatory cytokines increase intestinal perme-
ability, tissue injury and decreasing mtROS with MitoQ can
suppress this pathway and ameliorate inflammation during
colitis (Figure 7).
We here used DSS-induced acute colitis, because it is
one of the easiest, time- and cost-saving animal models.
Actually, DSS has a direct toxic effect on colonic epithe-
lium leading to a leaky tight junction and bacterial trans-
location. Therefore, this animal model may reflect an
acute injury model rather than an inflammatory disease,
indicating that it has a limitation to be used as a good
IBD model [63]. Currently, more than 60 animal models
are available for the study of IBD, but no individual
model can fully reflect human IBD [64,65]. In some cases,
investigators have used IL-10 knock-out or TNF (ARE)-
deleted mice to study the mechanisms of IBD pathogenesis
[66-69]. We have first shown the therapeutic effect of
MitoQ on IBD using the DSS-induced acute colitis model.
To clarify MitoQ effect on IBD more clearly, additional
tests will be needed in other well-established animal models
such as IL-10 knock-out mice. If carefully designed studies
show the positive effect of MitoQ on IBD treatment in di-
verse animal models, MitoQ may ultimately be tested in
human patients with IBD.
Conclusion
We suggest that mtROS are an important causative
factor in the pathogenesis of IBD. We showed that
MitoQ ameliorates acute colonic injury in a mouse
model of colitis not only by its antioxidative effects but
also by anti-inflammatory effects that suppress the
maturation of pro-inflammatory cytokines IL-1 beta
and IL-18. Considering the potent protective role of
MitoQ in an experimental model of colitis and its
proven safety in human clinical trials, MitoQ is a possibletherapeutic molecule for the treatment of acute phases
of IBD.
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